Hypothalamic-pituitary-adrenal (HPA) axis dysfunction has been found in a high proportion of chronic fatigue syndrome (CFS) patients and includes enhanced corticosteroid-induced negative feedback, basal hypocortisolism, attenuated diurnal variation, and a reduced responsivity to challenge. A putative causal role for genetic profile, childhood trauma, and oxidative stress has been considered. In addition, the impact of gender is demonstrated by the increased frequency of HPA axis dysregulation in females. Despite the temporal relationship, it is not yet established whether the endocrine dysregulation is causal, consequent, or an epiphenomenon of the disorder. Nonetheless, given the interindividual variation in the effectiveness of existing biological and psychological treatments, the need for novel treatment strategies such as those which target the HPA axis is clear. 1. Introduction Chronic fatigue syndrome (CFS) is a debilitating illness which was classified as a neurological disease in 1993 by the World Health Organisation (WHO) [1]. Symptoms of CFS include persistent fatigue, difficulty with memory and concentration, a disturbed sleep pattern, and severe muscular-skeletal pain [2]. Post exertional exacerbation of symptoms is common but not invariable [3]. The symptoms displayed vary markedly from patient to patient; some patients remain bedridden for very long periods of time, while others are able to manage their fatigue by staying within their own energy boundaries [4]. Diagnostic reliability is enhanced by the use of operational criteria such the Centre for Disease Control and Prevention Criteria [5], the Oxford Criteria [6] or the International Consensus Criteria [7, 8]. However, the heterogeneous symptom profile and absence of clear biological markers militate against confidence in the validity of CFS as a unitary diagnosis. It is not known, for instance, whether there is a core set of biological processes which underlie all cases of CFS or whether there are multiple processes (and if so, whether or not these potentially disparate processes converge on a final common pathway) [9]. Dysregulation of the biological systems which mediate the response to stress potentially has an important role in the aetiopathogenesis of CFS [1, 4, 10]. The neurobiological stress system comprises a range of networks that form intricate pathways; an important part of this is the hypothalamic-pituitary-adrenal (HPA) axis [11–14] which is a self-regulated feedback system which contributes to the maintenance of homeostasis and which is impacted by multiple factors such
References
[1]
A. Chaudhuri and P. O. Behan, “Neurological dysfunction in chronic fatigue syndrome,” Journal of Chronic Fatigue Syndrome, vol. 6, no. 3-4, pp. 51–68, 2000.
[2]
H. C. Atkinson, J. D. Leggett, S. A. Wood, E. S. Castrique, Y. M. Kershaw, and S. L. Lightman, “Regulation of the hypothalamic-pituitary-adrenal axis circadian rhythm by endocannabinoids is sexually diergic,” Endocrinology, vol. 151, no. 8, pp. 3720–3727, 2010.
[3]
J. E. Ottenweller, S. A. Sisto, R. C. McCarty, and B. H. Natelson, “Hormonal responses to exercise in chronic fatigue syndrome,” Neuropsychobiology, vol. 43, no. 1, pp. 34–41, 2001.
[4]
B. Van Houdenhove, F. V. D. Eede, and P. Luyten, “Does hypothalamic-pituitary-adrenal axis hypofunction in chronic fatigue syndrome reflect a 'crash' in the stress system?” Medical Hypotheses, vol. 72, no. 6, pp. 701–705, 2009.
[5]
K. Fukuda, S. E. Straus, I. Hickie, M. C. Sharpe, J. G. Dobbins, and A. Komaroff, “The chronic fatigue syndrome: a comprehensive approach to its definition and study,” Annals of Internal Medicine, vol. 121, no. 12, pp. 953–959, 1994.
[6]
M. C. Sharpe, L. C. Archard, J. E. Banatvala et al., “A report—chronic fatigue syndrome: guidelines for research,” Journal of the Royal Society of Medicine, vol. 84, no. 2, pp. 118–121, 1991.
[7]
B. M. Carruthers, M. I. Van de Sande, K. L. De Meirleir et al., “Myalgic encephalomyelitis: international Consensus Criteria,” Journal of Internal Medicine, vol. 270, no. 4, pp. 327–338, 2011.
[8]
A. S. Papadopoulos and A. J. Cleare, “Hypothalamic-pituitary-adrenal axis dysfunction in chronic fatigue syndrome,” Nature Reviews Endocrinology, vol. 8, no. 1, pp. 22–32, 2012.
[9]
J. R. V. Usón and M. á. I. Alecha, “Diagnostic and treatment challenges of chronic fatigue syndrome: role of immediate-release methylphenidate,” Expert Review of Neurotherapeutics, vol. 8, no. 6, pp. 917–927, 2008.
[10]
A. Beaumont, A. R. Burton, J. Lemon, B. K. Bennett, A. Lloyd, and U. Vollmer-Conna, “Reduced cardiac vagal modulation impacts on cognitive performance in chronic fatigue syndrome,” PLoS ONE, vol. 7, no. 11, Article ID e49518, 2012.
[11]
S. M. Smith and W. W. Vale, “The role of the hypothalamic-pituitary-adrenal axis in neuroendocrine responses to stress,” Dialogues in Clinical Neuroscience, vol. 8, no. 4, pp. 383–395, 2006.
[12]
I. J. Elenkov and G. P. Chrousos, “Stress system: organization, physiology and immunoregulation,” NeuroImmunoModulation, vol. 13, no. 5-6, pp. 257–267, 2007.
[13]
L. Lanfumey, R. Mongeau, C. Cohen-Salmon, and M. Hamon, “Corticosteroid-serotonin interactions in the neurobiological mechanisms of stress-related disorders,” Neuroscience and Biobehavioral Reviews, vol. 32, no. 6, pp. 1174–1184, 2008.
[14]
L. Jason, M. Sorenson, K. Sebally et al., “Increased HDAC in association with decreased plasma cortisol in older adults with chronic fatigue syndrome,” Brain, Behavior, and Immunity, vol. 25, no. 8, pp. 1544–1547, 2011.
[15]
B. M. Kudielka, N. C. Schommer, D. H. Hellhammer, and C. Kirschbaum, “Acute HPA axis responses, heart rate, and mood changes to psychosocial stress (TSST) in humans at different times of day,” Psychoneuroendocrinology, vol. 29, no. 8, pp. 983–992, 2004.
[16]
A. J. Cleare, “The neuroendocrinology of chronic fatigue syndrome,” Endocrine Reviews, vol. 24, no. 2, pp. 236–252, 2003.
[17]
A. M. Bao, G. Meynen, and D. F. Swaab, “The stress system in depression and neurodegeneration: focus on the human hypothalamus,” Brain Research Reviews, vol. 57, no. 2, pp. 531–553, 2008.
[18]
C. M. Pariante and S. L. Lightman, “The HPA axis in major depression: classical theories and new developments,” Trends in Neurosciences, vol. 31, no. 9, pp. 464–468, 2008.
[19]
A. Ben-Zvi, S. D. Vernon, and G. Broderick, “Model-based therapeutic correction of hypothalamic-pituitary-adrenal axis dysfunction,” PLoS Computational Biology, vol. 5, no. 1, Article ID e1000273, 2009.
[20]
J. Gaab, V. Engert, V. Heitz, T. Schad, T. H. Schürmeyer, and U. Ehlert, “Associations between neuroendocrine responses to the Insulin Tolerance Test and patient characteristics in chronic fatigue syndrome,” Journal of Psychosomatic Research, vol. 56, no. 4, pp. 419–424, 2004.
[21]
A. Poteliakhoff, “Adrenocortical activity and some clinical findings in acute and chronic fatigue,” Journal of Psychosomatic Research, vol. 25, no. 2, pp. 91–95, 1981.
[22]
L. M. Tak, A. J. Cleare, J. Ormel et al., “Meta-analysis and meta-regression of hypothalamic-pituitary-adrenal axis activity in functional somatic disorders,” Biological Psychology, vol. 87, no. 2, pp. 183–194, 2011.
[23]
V. B. Wyller, “The chronic fatigue syndrome: an update,” Acta Neurologica Scandinavica, vol. 115, no. 187, pp. 7–14, 2007.
[24]
W. K. Jerjes, A. J. Cleare, S. Wessely, P. J. Wood, and N. F. Taylor, “Diurnal patterns of salivary cortisol and cortisone output in chronic fatigue syndrome,” Journal of Affective Disorders, vol. 87, no. 2-3, pp. 299–304, 2005.
[25]
A. Di Giorgio, M. Hudson, W. Jerjes, and A. J. Cleare, “24-Hour pituitary and adrenal hormone profiles in chronic fatigue syndrome,” Psychosomatic Medicine, vol. 67, no. 3, pp. 433–440, 2005.
[26]
L. J. Crofford, E. A. Young, N. C. Engleberg et al., “Basal circadian and pulsatile ACTH and cortisol secretion in patients with fibromyalgia and/or chronic fatigue syndrome,” Brain, Behavior, and Immunity, vol. 18, no. 4, pp. 314–325, 2004.
[27]
B. S. McEwen, “Central effects of stress hormones in health and disease: understanding the protective and damaging effects of stress and stress mediators,” European Journal of Pharmacology, vol. 583, no. 2-3, pp. 174–185, 2008.
[28]
F. Van Den Eede, G. Moorkens, W. Hulstijn et al., “Combined dexamethasone/corticotropin-releasing factor test in chronic fatigue syndrome,” Psychological Medicine, vol. 38, no. 7, pp. 963–970, 2008.
[29]
W. J. Inder, T. C. R. Prickett, and R. T. Mulder, “Normal opioid tone and hypothalamic-pituitary-adrenal axis function in chronic fatigue syndrome despite marked functional impairment,” Clinical Endocrinology, vol. 62, no. 3, pp. 343–348, 2005.
[30]
H. B. Izgi, C. G?k?e, M. ?ali? et al., “Investigation of the hypothalamopituitary-adrenal axis by low-dose (1?μg) adrenocorticotrophic hormone test and metyrapone test in patients with chronic fatigue syndrome,” Endocrinologist, vol. 15, no. 2, pp. 89–92, 2005.
[31]
J. Gaab, N. Rohleder, V. Heitz et al., “Stress-induced changes in LPS-induced pro-inflammatory cytokine production in chronic fatigue syndrome,” Psychoneuroendocrinology, vol. 30, no. 2, pp. 188–198, 2005.
[32]
S. Melmed and D. Kleinberg, Williams Textbook of Endocrinology, Saunders, 10th edition, 2003.
[33]
C. Heim, U. M. Nater, E. Maloney, R. Boneva, J. F. Jones, and W. C. Reeves, “Childhood trauma and risk for chronic fatigue syndrome Association with Neuroendocrine Dysfunction,” Archives of General Psychiatry, vol. 66, no. 1, pp. 72–80, 2009.
[34]
U. M. Nater, E. Maloney, R. S. Boneva et al., “Attenuated morning salivary cortisol concentrations in a population-based study of persons with chronic fatigue syndrome and well controls,” Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 3, pp. 703–709, 2008.
[35]
S. Gupta, E. Aslakson, B. M. Gurbaxani, and S. D. Vernon, “Inclusion of the glucocorticoid receptor in a hypothalamic pituitary adrenal axis model reveals bistability,” Theoretical Biology and Medical Modelling, vol. 4, article 8, 2007.
[36]
J. Gaab, D. Hüster, R. Peisen et al., “Low-dose dexamethasone suppression test in chronic fatigue syndrome and health,” Psychosomatic Medicine, vol. 64, no. 2, pp. 311–318, 2002.
[37]
F. Van Den Eede, G. Moorkens, B. Van Houdenhove, P. Cosyns, and S. J. Claes, “Hypothalamic-pituitary-adrenal axis function in chronic fatigue syndrome,” Neuropsychobiology, vol. 55, no. 2, pp. 112–120, 2007.
[38]
W. K. Jerjes, N. F. Taylor, P. J. Wood, and A. J. Cleare, “Enhanced feedback sensitivity to prednisolone in chronic fatigue syndrome,” Psychoneuroendocrinology, vol. 32, no. 2, pp. 192–198, 2007.
[39]
J. C. Ritchie, B. M. Belkin, K. Ranga, R. R. Krishnan, C. B. Nemeroff, and B. J. Carroll, “Plasma dexamethasone concentrations and the dexamethasone suppression test,” Biological Psychiatry, vol. 27, no. 2, pp. 159–173, 1990.
[40]
T. Turan, H. B. Izgi, S. Ozsoy et al., “The effects of galantamine hydrobromide treatment on dehydroepiandrosterone sulfate and cortisol levels in patients with chronic fatigue syndrome,” Psychiatry Investigation, vol. 6, no. 3, pp. 204–210, 2009.
[41]
A. J. Cleare, V. O'Keane, and J. P. Miell, “Levels of DHEA and DHEAS and responses to CRH stimulation and hydrocortisone treatment in chronic fatigue syndrome,” Psychoneuroendocrinology, vol. 29, no. 6, pp. 724–732, 2004.
[42]
P. B. Himmel and T. M. Seligman, “A pilot study employing Dehydroepiandrosterone (DHEA) in the treatment of chronic fatigue syndrome,” Journal of Clinical Rheumatology, vol. 5, no. 2, pp. 56–59, 1999.
[43]
M. Maes, I. Mihaylova, and M. De Ruyter, “Decreased dehydroepiandrosterone sulfate but normal insulin-like growth factor in chronic fatigue syndrome (CFS): relevance for the inflammatory response in CFS,” Neuroendocrinology Letters, vol. 26, no. 5, pp. 487–492, 2005.
[44]
L. V. Scott, F. Svec, and T. Dinan, “A preliminary study of dehydroepiandrosterone response to low-dose ACTH in chronic fatigue syndrome and in healthy subjects,” Psychiatry Research, vol. 97, no. 1, pp. 21–28, 2000.
[45]
F. Albright, K. Light, A. Light, L. Bateman, and L. A. Cannon-Albright, “Evidence for a heritable predisposition to chronic fatigue syndrome,” BMC Neurology, vol. 11, article 62, 2011.
[46]
S. Kempke, P. Luyten, S. Claes et al., “The prevalence and impact of early childhood trauma in Chronic Fatigue Syndrome,” Of Psychiatric Research, vol. 47, no. 5, pp. 664–669, 2013.
[47]
F. Van Den Eede, T. Haccuria, M. De Venter, and G. Moorkens, “Childhood sexual abuse and chronic fatigue syndrome,” British Journal of Psychiatry, vol. 200, no. 2, pp. 164–165, 2012.
[48]
C. Heim, D. Wagner, E. Maloney et al., “Early adverse experience and risk for chronic fatigue syndrome: results from a population-based study,” Archives of General Psychiatry, vol. 63, no. 11, pp. 1258–1266, 2006.
[49]
J. D. Coplan, M. W. Andrews, L. A. Rosenblum et al., “Persistent elevations of cerebrospinal fluid concentrations of corticotropin-releasing factor in adult nonhuman primates exposed to early-life stressors: implications for the pathophysiology of mood and anxiety disorders,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 4, pp. 1619–1623, 1996.
[50]
I. C. G. Weaver, “Epigenetic programming by maternal behavior and pharmacological intervention—nature versus nurture: let's call the whole thing off,” Epigenetics, vol. 2, no. 1, pp. 22–28, 2007.
[51]
I. C. G. Weaver, N. Cervoni, F. A. Champagne et al., “Epigenetic programming by maternal behavior,” Nature Neuroscience, vol. 7, no. 8, pp. 847–854, 2004.
[52]
T. F. Oberlander, J. Weinberg, M. Papsdorf, R. Grunau, S. Misri, and A. M. Devlin, “Prenatal exposure to maternal depression, neonatal methylation of human glucocorticoid receptor gene (NR3C1) and infant cortisol stress responses,” Epigenetics, vol. 3, no. 2, pp. 97–106, 2008.
[53]
K. M. Radtke, M. Ruf, H. M. Gunter et al., “Transgenerational impact of intimate partner violence on methylation in the promoter of the glucocorticoid receptor,” Translational Psychiatry, vol. 1, article e21, 2011.
[54]
P. O. McGowan, A. Sasaki, A. C. D'Alessio et al., “Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse,” Nature Neuroscience, vol. 12, no. 3, pp. 342–348, 2009.
[55]
N. Perroud, A. Dayer, C. Piguet et al., “Childhood maltreatment and methylation of the glucocorticoid receptor gene NR3C1 in bipolar disorder,” British Journal of Psychiatry, 2013.
[56]
N. Perroud, A. Paoloni-Giacobino, P. Prada et al., “Increased methylation of glucocorticoid receptor gene (NR3C1) in adults with a history of childhood maltreatment: a link with the severity and type of trauma,” Translational Psychiatry, vol. 1, article e59, 2011.
[57]
P. O. McGowan, M. Suderman, A. Sasaki et al., “Broad epigenetic signature of maternal care in the brain of adult rats,” PLoS ONE, vol. 6, no. 2, Article ID e14739, 2011.
[58]
B. Labonté, M. Suderman, G. Maussion et al., “Genome-wide epigenetic regulation by early-life trauma,” Archives of General Psychiatry, vol. 69, no. 7, pp. 722–731, 2012.
[59]
D. Collip, I. Myin-Germeys, M. Wichers et al., “FKBP5 as a possible moderator of the psychosis-inducing effects of childhood trauma,” British Journal of Psychiatry, vol. 202, no. 5, pp. 261–268, 2013.
[60]
W. B. Pratt and D. O. Toft, “Steroid receptor interactions with heat shock protein and immunophilin chaperones,” Endocrine Reviews, vol. 18, no. 3, pp. 306–360, 1997.
[61]
T. Klengel, D. Mehta, C. Anacker et al., “Allele-specific FKBP5 DNA demethylation mediates gene-childhood trauma interactions,” Nature Neuroscience, vol. 16, no. 1, pp. 33–41, 2013.
[62]
M. H. Teicher, C. M. Anderson, and A. Polcari, “Childhood maltreatment is associated with reduced volume in the hippocampal subfields CA3, dentate gyrus,and subiculum,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 9, pp. E563–E572, 2012.
[63]
B. Grinde, “Is chronic fatigue syndrome caused by a rare brain infection of a common, normally benign virus?” Medical Hypotheses, vol. 71, no. 2, pp. 270–274, 2008.
[64]
B. S. McEwen, “Seminars in medicine of the Beth Israel Deaconess Medical Center: protective and damaging effects of stress mediators,” New England Journal of Medicine, vol. 338, no. 3, pp. 171–179, 1998.
[65]
S. B. Harvey, M. Wadsworth, S. Wessely, and M. Hotopf, “The relationship between prior psychiatric disorder and chronic fatigue: evidence from a national birth cohort study,” Psychological Medicine, vol. 38, no. 7, pp. 933–940, 2008.
[66]
E. Fries, “Hypocortisolemic disorders,” in Stress: The Brain-Body Connection. Key Issues in Mental Health, D. H. Hellhammer and J. Hellhammer, Eds., vol. 174, pp. 60–77, 2008.
[67]
V. O'Keane, T. Frodl, and T. G. Dinan, “A review of atypical depression in relation to the course of depression and changes in HPA axis organization,” Psychoneuroendocrinology, vol. 37, no. 10, pp. 1589–1599, 2012.
[68]
L. V. Scott and T. G. Dinan, “Vasopressin and the regulation of hypothalamic-pituitary-adrenal axis function: implications for the pathophysiology of depression,” Life Sciences, vol. 62, no. 22, pp. 1985–1998, 1998.
[69]
A. P. Harris, M. C. Holmes, E. R. de Kloet, K. E. Chapman, and J. R. Seckl, “Mineralocorticoid and glucocorticoid receptor balance in control of HPA axis and behaviour,” Psychoneuroendocrinology, vol. 38, no. 5, pp. 648–658, 2013.
[70]
E. R. De Kloet, E. Vreugdenhil, M. S. Oitzl, and M. Jo?ls, “Brain corticosteroid receptor balance in health and disease,” Endocrine Reviews, vol. 19, no. 3, pp. 269–301, 1998.
[71]
M. V. Flinn, “Evolution and ontogeny of stress response to social challenges in the human child,” Developmental Review, vol. 26, no. 2, pp. 138–174, 2006.
[72]
D. K. Surapaneni, Adapa SRSS, K. Preeti, G. R. Teja, M. Veeraragavan, and S. Krishnamurthy, “Shilajit attenuates behavioral symptoms of chronic fatigue syndrome by modulating the hypothalamic-pituitary-adrenal axis and mitochondrial bioenergetics in rats,” Journal of Ethnopharmacology, vol. 143, no. 1, pp. 91–99, 2012.
[73]
C. L. Raison and A. H. Miller, “Malaise, melancholia and madness: the evolutionary legacy of an inflammatory bias,” Brain, Behavior and Immunity, vol. 31, pp. 1–8, 2013.
[74]
F. Martinon, A. Mayor, and J. Tschopp, “The inflammasomes: guardians of the body,” Annual Review of Immunology, vol. 27, pp. 229–265, 2009.
[75]
M. ter Wolbeek, L. J. P. van Doornen, A. Kavelaars, E. M. van de Putte, M. Schedlowski, and C. J. Heijnen, “Longitudinal analysis of pro- and anti-inflammatory cytokine production in severely fatigued adolescents,” Brain, Behavior, and Immunity, vol. 21, no. 8, pp. 1063–1074, 2007.
[76]
G. E. Miller, E. Chen, J. Sze et al., “A functional genomic fingerprint of chronic stress in humans: blunted glucocorticoid and increased NF-κB signaling,” Biological Psychiatry, vol. 64, no. 4, pp. 266–272, 2008.
[77]
A. V. Turnbull and C. L. Rivier, “Regulation of the hypothalamic-pituitary-adrenal axis by cytokines: actions and mechanisms of action,” Physiological Reviews, vol. 79, no. 1, pp. 1–71, 1999.
[78]
B. Van Houdenhove and P. Luyten, “Customizing treatment of chronic fatigue syndrome and fibromyalgia: the role of perpetuating factors,” Psychosomatics, vol. 49, no. 6, pp. 470–477, 2008.
[79]
L. Lewis, J. Pairman, G. Spickett, and J. Newton, “Clinical characteristics of a novel subgroup of chronic fatigue syndrome patients with postural orthostatic tachycardia syndrome,” Journal of Internal Medicine, vol. 273, no. 5, pp. 501–510, 2013.
[80]
A. Hoad, G. Spickett, J. Elliott, and J. Newton, “Postural orthostatic tachycardia syndrome is an under-recognized condition in chronic fatigue syndrome,” QJM, vol. 101, no. 12, pp. 961–965, 2008.
[81]
J. F. Thayer and E. Sternberg, “Beyond heart rate variability: vagal regulation of allostatic systems,” Annals of the New York Academy of Sciences, vol. 1088, pp. 361–372, 2006.
[82]
A. D. L. Roberts, S. Wessely, T. Chalder, A. Papadopoulos, and A. J. Cleare, “Salivary cortisol response to awakening in chronic fatigue syndrome,” British Journal of Psychiatry, vol. 184, pp. 136–141, 2004.
[83]
J. Bearn and S. Wessely, “Neurobiological aspects of the chronic fatigue syndrome,” European Journal of Clinical Investigation, vol. 24, no. 2, pp. 79–90, 1994.
[84]
L. Jason, K. Muldowney, and S. Torres-Harding, “The Energy Envelope Theory and myalgic encephalomyelitis/chronic fatigue syndrome,” AAOHN Journal, vol. 56, no. 5, pp. 189–195, 2008.
[85]
J. C. Van Denderen, J. W. Boersma, P. Zeinstra, A. P. Hollander, and B. R. Van Neerbos, “Physiological effects of exhaustive physical exercise in primary fibromyalgia syndrome (PFS): is PFS a disorder of neuroendocrine reactivity?” Scandinavian Journal of Rheumatology, vol. 21, no. 1, pp. 35–37, 1992.
[86]
J. K. Prague, S. May, and B. C. Whitelaw, “Cushing's syndrome,” BMJ, vol. 346, article f945, 2013.
[87]
S. B. Sarkar, S. Sarkar, S. Ghosh, and S. Bandyopadhyay, “Addison's disease,” Contemporary Clinical Dentistry, vol. 3, no. 4, pp. 484–486, 2012.
[88]
A. J. Cleare, “The HPA axis and the genesis of chronic fatigue syndrome,” Trends in Endocrinology and Metabolism, vol. 15, no. 2, pp. 55–59, 2004.
[89]
R. Moss-Morris, C. Sharon, R. Tobin, and J. C. Baldi, “A randomized controlled graded exercise trial for chronic fatigue syndrome: outcomes and mechanisms of change,” Journal of Health Psychology, vol. 10, no. 2, pp. 245–259, 2005.
[90]
J. B. Prins, J. W. M. Van Der Meer, and G. Bleijenberg, “Chronic fatigue syndrome,” Lancet, vol. 367, no. 9507, pp. 346–355, 2006.
[91]
P. Whiting, A. M. Bagnall, A. J. Sowden, J. E. Cornell, C. D. Mulrow, and G. Ramírez, “Interventions for the treatment and management of chronic fatigue syndrome: a systematic review,” Journal of the American Medical Association, vol. 286, no. 11, pp. 1360–1368, 2001.
[92]
M. P. Davis, D. Khoshknabi, and G. H. Yue, “Management of fatigue in cancer patients,” Current Pain and Headache Reports, vol. 10, no. 4, pp. 260–269, 2006.
[93]
P. J. Goodnick and R. Sandoval, “Psychotropic treatment of chronic fatigue syndrome and related disorders,” Journal of Clinical Psychiatry, vol. 54, no. 1, pp. 13–20, 1993.
[94]
J. Gaab, D. Hüster, R. Peisen et al., “Hypothalamic-pituitary-adrenal axis reactivity in chronic fatigue syndrome and health under psychological, physiological, and pharmacological stimulation,” Psychosomatic Medicine, vol. 64, no. 6, pp. 951–962, 2002.
[95]
B. H. Natelson, J. Cheu, N. Hill et al., “Single-blind, placebo phase-in trial of two escalating doses of selegiline in the chronic fatigue syndrome,” Neuropsychobiology, vol. 37, no. 3, pp. 150–154, 1998.
[96]
R. McKenzie, A. O'Fallon, J. Dale et al., “Low-dose hydrocortisone for treatment of chronic fatigue syndrome: a randomized controlled trial,” Journal of the American Medical Association, vol. 280, no. 12, pp. 1061–1066, 1998.
[97]
A. J. Cleare, J. Miell, E. Heap et al., “Hypothalamo-pituitary-adrenal axis dysfunction in chronic fatigue syndrome, and the effects of low-dose hydrocortisone therapy,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 8, pp. 3545–3554, 2001.
[98]
K. Holtorf, “Diagnosis and treatment of hypothalamic-pituitary-adrenal (HPA) axis dysfunction in patients with chronic fatigue syndrome (CFS) and fibromyalgia (FM),” Journal of Chronic Fatigue Syndrome, vol. 14, no. 3, pp. 59–88, 2008.
[99]
A. L. Buchman, “Side effects of corticosteroid therapy,” Journal of Clinical Gastroenterology, vol. 33, no. 4, pp. 289–294, 2001.
[100]
H. G. Kim, J. S. Lee, J. M. Han et al., “Myelophil attenuates brain axidative damage by modulating the hypothalamus-pituitary-adrenal (HPA) axis in a chronic cold-stress mouse model,” Journal of Ethnopharmacology, vol. 148, no. 2, pp. 505–515, 2013.
[101]
C. Krishna, “New research body to look at chronic fatigue syndrome,” BMJ, vol. 346, article f2630, 2013.